Literature DB >> 23010731

1 or 2 cm margins of excision for T2 melanomas: do they impact recurrence or survival?

Laura E Hudson1, Shishir K Maithel, Grant W Carlson, Monica Rizzo, Douglas R Murray, Andrea C Hestley, Keith A Delman.   

Abstract

BACKGROUND: NCCN guidelines recommend 1 or 2 cm margins for melanomas 1-2 mm (T2 melanomas) in depth; however, no head-to-head comparison has been performed. We hypothesized 1- or 2-cm margins would have similar local recurrence (LR) and overall survival (OS).
METHODS: An institutional database was queried for patients with 1.0-2.0 mm melanomas treated from July 1995 to January 2011. All had wide excision and sentinel lymph node biopsy. Patients without documented surgical margins or follow-up were excluded. Clinicopathologic and recurrence data were reviewed. Univariate and multivariate analyses were performed.
RESULTS: Of 2,118 patients, 1,225 met study criteria. Of these, 576 had complete data: 224 (38.9%) had 1 cm margins and 352 (61.1%), 2 cm margins. Median follow-up was 38 months. Mean age was 52.6 years (range 11.3-86.7). Mean thickness was 1.27 and 1.48 mm (1 and 2 cm, respectively, p<0.001) with ulceration more common in the 2 cm group (12.3 and 21.3%, respectively; p=0.009). LR was 3.6 and 0.9% in the 1 cm versus 2 cm group, respectively (p=0.044). OS was 29.1 months with 1 cm and 43.7 months in the 2 cm group. On multivariate analysis, only head and neck location and nodal status were associated with overall survival.
CONCLUSIONS: In this series, 1 cm margins were associated with a small increase in LR that did not impact OS. This is concordant with the NCCN recommendations; however, a prospective, randomized trial would be optimal.

Entities:  

Mesh:

Year:  2012        PMID: 23010731     DOI: 10.1245/s10434-012-2543-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Analysis of recurrence patterns in acral versus nonacral melanoma: should histologic subtype influence treatment guidelines?

Authors:  Priyanka V Gumaste; Nathaniel H Fleming; Ines Silva; Richard L Shapiro; Russell S Berman; Judy Zhong; Iman Osman; Jennifer A Stein
Journal:  J Natl Compr Canc Netw       Date:  2014-12       Impact factor: 11.908

2.  Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?

Authors:  Matthew C Perez; Felipe R de Pinho; Amanda Holstein; Daniel E Oliver; Syeda M H Naqvi; Youngchul Kim; Jane L Messina; Erin Burke; Ricardo J Gonzalez; Amod A Sarnaik; C Wayne Cruse; Evan J Wuthrick; Louis B Harrison; Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2018-08-02       Impact factor: 5.344

3.  Is a Wider Margin (2 cm vs. 1 cm) for a 1.01-2.0 mm Melanoma Necessary?

Authors:  Matthew P Doepker; Zachary J Thompson; Kate J Fisher; Maki Yamamoto; Kevin W Nethers; Jennifer N Harb; Matthew A Applebaum; Ricardo J Gonzalez; Amod A Sarnaik; Jane L Messina; Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2016-03-08       Impact factor: 5.344

Review 4.  Essential Components of Melanoma Histopathological Reporting: The Surgical Oncologist's Perspective.

Authors:  Vinka Nurdjaja; Masato Yozu; Jon A Mathy
Journal:  J Skin Cancer       Date:  2018-05-02

Review 5.  Evidence from Clinical Studies Related to Dermatologic Surgeries for Skin Cancer.

Authors:  Shoichiro Ishizuki; Yoshiyuki Nakamura
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

6.  Melanoma-Derived BRAF(V600E) Mutation in Peritumoral Stromal Cells: Implications for in Vivo Cell Fusion.

Authors:  Zsuzsanna Kurgyis; Lajos V Kemény; Tünde Buknicz; Gergely Groma; Judit Oláh; Ádám Jakab; Hilda Polyánka; Kurt Zänker; Thomas Dittmar; Lajos Kemény; István B Németh
Journal:  Int J Mol Sci       Date:  2016-06-21       Impact factor: 5.923

7.  Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial.

Authors:  Andrew J Hayes; Lauren Maynard; Gillian Coombes; Julia Newton-Bishop; Michael Timmons; Martin Cook; Jeffrey Theaker; Judith M Bliss; J Meirion Thomas
Journal:  Lancet Oncol       Date:  2016-01-12       Impact factor: 41.316

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.